Results 51 to 60 of about 785,669 (310)

Supplemental data Figure 1 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

open access: yes, 2008
Supplemental data Figure 1 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against ...
Steven Duniho (14973184)   +11 more
core   +1 more source

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

open access: yesFEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson   +2 more
wiley   +1 more source

The Humanization and Maturation of an Anti-PrPc Antibody

open access: yesBioengineering
The cellular prion protein (PrPc) is a cell surface glycoprotein that is highly expressed in a variety of cancer tissues in addition to the nervous system, and its elevated expression is correlated to poor prognosis in many cancer patients.
Cheng Zhang   +9 more
doaj   +1 more source

New targeted treatments for cutaneous T-cell Lymphomas

open access: yesIndian Journal of Dermatology, 2017
Cutaneous T-cell lymphomas (CTCLs) represent a group of rare and heterogeneous diseases that are very difficult to treat at advanced stages. The development of monoclonal antibodies is a new hope for the treatment of these diseases. Alemtuzumab (Campath)
Martine Bagot
doaj   +1 more source

Supplemental data Figure 3 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

open access: yes, 2008
Supplemental data Figure 3 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against ...
Steven Duniho (14973184)   +11 more
core   +1 more source

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui   +10 more
wiley   +1 more source

TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. [PDF]

open access: yesPLoS ONE, 2016
Therapeutic monoclonal antibodies (mAbs) such as the superagonistic, CD28-specific antibody TGN1412, or OKT3, an anti-CD3 mAb, can cause severe adverse events including cytokine release syndrome.
Sabrina Weißmüller   +7 more
doaj   +1 more source

Supplemental data Figure 4 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

open access: yes, 2008
Supplemental data Figure 4 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against ...
Steven Duniho (14973184)   +11 more
core   +1 more source

Antibody‐Protein L Functionalized Microparticles for Detection of Surface Markers in Heterogeneous Colorectal Lesions

open access: yesAdvanced Healthcare Materials, EarlyView.
Personalized targeting of colorectal cancer (CRC) is challenged by the heterogeneity of the disease and its variable display of tumor surface markers. Antibody‐Protein L Microparticles (APL‐MPs) leverage the antibody‐binding property of Protein L in a swappable system, enabling easy application to variable targets for personalized therapies.
Saleh Ramezani   +11 more
wiley   +1 more source

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy

open access: yesTranslational Oncology
Bispecific antibodies (BsAbs) represent a promising strategy for cancer immunotherapy. Challenges in immunotherapy include inefficient early events in the immune response cycle, such as antigen presentation and T cell priming.
Kun Du, He Huang
doaj   +1 more source

Home - About - Disclaimer - Privacy